Navigation Links
Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer
Date:4/29/2009

CHICAGO, ILSipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were presented during the meeting's Late Breaking Science Forum.

Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded the pre-specified level of statistical significance defined by the study's design and reduced the overall risk of death by 22.5 percent compared to placebo (p-value=0.032). More than 500 patients were enrolled in the IMPACT trial, a multi-center, randomized, double-blind, placebo-controlled study evaluating men with asymptomatic or minimally symptomatic, metastatic, androgen-independent prostate cancer. The primary endpoint was overall survival.

Researchers are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo.

"The ability to boost survival for patients is the gold standard endpoint in prostate cancer clinical trials," said AUA spokesperson Ira D. Sharlip, MD. "The ability to give these patients both increased survival and possibly, improved quality of life, is very important."

Sipuleucel-T is an investigational therapy for men with androgen-independent prostate cancer. It is an active cellular immunotherapy designed to use live human cells to boost a patient's immune system to elicit a long-lasting response against cancer.


'/>"/>

Contact: Wendy Isett
wisett@auanet.org
410-977-4770
American Urological Association
Source:Eurekalert

Page: 1

Related medicine news :

1. Statins alter prostate cancer patients PSA levels
2. Living and Loving with Prostate Cancer: Men Deserve Better
3. Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk
4. AUA Counters Mainstream Recommendations with New Best Practice Statement on Prostate-Specific Antigen Testing
5. Heart, Bone Problems May Follow Prostate Cancer Treatment
6. Prostate Study Shows BOTOX May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia
7. Prostate cancer therapy increases risk of fractures and cardiovascular-related death
8. Statins Guard Against Prostate Cancer
9. Statins may exert influence on prostate cancer growth by reducing inflammation
10. Major statin study reveals several important findings for reducing prostate cancer and disease
11. Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, Fumie ... on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East Side, ... such as Zen Kodo mat. Wanderlust , one of the largest US yoga ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... of the Month, Lewis and Clark College Emeritus Professor of Education Gregory A. ... Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... of providing a voice for people who have kidney disease. The theme “Describe ... to share their stories. Entrants needed to meet only one qualification— to ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... the Orthodontics and Clear Aligner clinical and commercial support services market) has entered ... Dentistry (PGSD) in Sydney, Australia. , The PGSD is the first private ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... social campaign, “Humans With Vaginas.” The goal is to ignite conversation via social ... personal care products. The brand has declared September “Humans with Vaginas” month, releasing ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: